Gastrointestinal-related complications in a long-term care population taking NSAIDS versus COX-2 inhibitor therapy

Consultant Pharmacist

Volumn 19, Issue 7, 2004, Pages 602-613

  Mann, Jodi L ^a   Evans, Tamara S ^b  

^a Department of Clinical Services   (United States)

^b PFIZER INC   (United States)

Author keywords

COX 2 inhibitor; Gastrointestinal disease; Hospitalization; Nonsteroidal anti inflammatory drug

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTICOAGULANT AGENT; ARTHROTEC; CELECOXIB; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; ESOMEPRAZOLE; FAMOTIDINE; GLUCOCORTICOID; IBUPROFEN; LANSOPRAZOLE; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; RANITIDINE; ROFECOXIB; SALSALATE; SIMETHICONE; SUCRALFATE; UNINDEXED DRUG; VALDECOXIB;

ADULT; AGED; ANALGESIA; ARTHRITIS; ARTICLE; ASSISTED LIVING FACILITY; BLEEDING; DRUG SAFETY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE FACILITY; HEARTBURN; HOSPITALIZATION; HUMAN; INCIDENCE; INTESTINE PERFORATION; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAID; NAUSEA; PEPTIC ULCER; PREVALENCE; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 3042781028     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2004.602     Document Type: Article

References (19)

1. Lawrence RC, Hochberg MC, Kelsey JL et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989;16:427-41.
2. Felts W, Yelin E. The economic impact of the rheumatic diseases in the United States. J Rheumatol 1989;16:867-84.
3. Anti-arthritic medication usage: United States, 1991. Stat Bull Metrop Insur Co. 1992;73:25-34.
4. Barrier CH, Hirschowitz BI. Controversies in the detection and management of non-steroidal anti-inflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989;32:926-32.
5. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99. [Erratum, N Engl J Med 1999;34:548.]
6. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99. [Erratum, N Engl J Med 1999;34:548.]
7. Singh G, Rosen Ramey D. NSAID-induced gastrointestinal complications: the ARAMIS perspective-1997. J Rheumatol (Suppl) 1998;51:s8-s16.
8. Smalley WE, Ray WA, Daugherty JR et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539-45.
9. Garcia Rodriguez LA, Walker AM, Perez Gutthann S. Nonsteroidal anti-inflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 1992;3:337-42.
10. Gabriel SE, Jaakkimainen L, Bombadier C. Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta analysis. Ann Intern Med 1991;115:787-96.
11. Henry D., Lim LL-Y, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
12. Bollini P, Garcia Rodriguez LA, Perez Gutthann S et al. The impact of research quality and study design on epidemiologic estimates of the effect of non-steroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992; 152:1289-92.
13. Garcia Rodriguez LA, Cattanuzzi C, Grazia Troncon M et al. Risk of hospitalizations for upper gastrointestinal tract bleeding associated with ketorolac, other non-steroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998;158:33-9.
14. Lapane KL, Spooner JJ, Mucha L et al. Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc 2001;49:577-84.
15. Learned RE, Glosner SE, Elbl J et al. Evaluation of concomitant nonsteroidal anti-inflammatory drug and gastrointestinal medication use in long-term care patients. Consult Pharm 2001;16:152-6.
16. Mamdani M, Rochon PA, Juurlink DN et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002;325:1-6.
17. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
18. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
19. Schnitzer TJ. Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage 2002;23(suppl):s24-s30.